Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access imatinib in adjuvant GIST after R0 resection
2008-003883-20Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of imatinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Primary endpoint: Safety and tolerability of imatinib. Started Jul 2008; status: completed.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2008-003883-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003883-20.